Nanosonics broadens CORIS reach with second FDA clearance

Second FDA Clearance Expands CORIS Indications

Nanosonics Limited (ASX:NAN) has received a second US Food and Drug Administration 510(k) clearance for its CORIS System, widening the range of flexible endoscopes that can be reprocessed with the device. The newly covered indications include a number of high-volume colonoscopes and gastroscopes, giving the system a broader addressable equipment base in the US.

The clearance builds on CORIS’s original De Novo authorisation and first 510(k) clearance. It marks another regulatory step for a product designed to automate the cleaning of endoscope channels, a critical stage before reusable endoscopes undergo further reprocessing.

US Launch Plans Move Through Regulatory Stages

The announcement arrives as Nanosonics advances CORIS towards commercialisation. In August, the company said regulatory approvals and a Controlled Market Release were underway as part of its CORIS commercial launch plans. The latest clearance supports the planned US launch activities, according to the company, while extending the device’s potential use across key endoscope categories.

Chief executive and president Michael Kavanagh described the clearance as an “important milestone” and said it demonstrated continued execution against the company’s regulatory and commercialisation strategy. He added that Nanosonics remained focused on progressively broadening CORIS indications across its key geographic markets.

Commercial Impact Remains Unquantified

The filing is positive on regulatory progress but light on commercial detail. Nanosonics does not identify the number of newly covered endoscope models, provide a US launch date, disclose commercial terms or quantify the expected effect on revenue and earnings. The clearance therefore improves the product’s regulatory coverage without, on its own, establishing the pace or scale of adoption.

That leaves the next evidence in the CORIS story likely to come from launch execution: which hospitals and healthcare providers adopt the system, how quickly the expanded indications translate into usage, and whether further clearances are needed to broaden the range again. Until those details emerge, the regulatory advance is clear while the financial payoff remains to be demonstrated.